Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting ...

I celebrated five years since my bone marrow transplant with a surprise video from my donor, a beautiful reminder of the life ...

Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...

Break Through Cancer, a Boston-based cancer research foundation, has launched a clinical trial to evaluate the feasibility of ...

The US Food and Drug Administration (FDA) has accepted the supplemental new drug application (sNDA) for Inqovi (decitabine ...

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts. On June 24, ...

An announcement from Moleculin Biotech ( ($MBRX) ) is now available. On July 9, 2025, Moleculin Biotech announced that the Regulation Agency for ...

Acute Myeloid Leukemia (AML), an aggressive form of blood cancer, has long been a significant challenge for patients and doctors in India. But recent medical breakthroughs—including the recent approva ...

Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.